From early concepts to validated candidates,
KumiChem™ supports every step of RNA drug discovery.
The same discovery path, compressed from weeks to hours
Indicative comparison for the in silico design stage.
Whether you are opening a new target or improving on an existing therapy, KumiChem™ supports both paths.
Explore novel RNA targets, including those out of reach for small molecules, and turn them into ranked starting points.
Design against known benchmarks and optimize for potency, safety and durability.
KumiChem™ supports the in silico design stage. All candidates require experimental validation.
KumiChem takes each target from sequence to lead: retrieving the full transcript, mapping splice sites and secondary structure to locate accessible binding sites, then generating large batches of chemically optimized ASO candidates at scale.
Every candidate is screened with in silico toxicity and safety evaluation, and cross-referenced against the patent landscape and latest clinical evidence. Multi-parameter filtering and ranking then prioritize the most promising, developable ASOs for experimental validation.
KumiChem streamlines siRNA development with off-target-aware sequence design, identifying optimal target sites from full mRNA sequences using isoform-aware, structure-guided accessibility analysis.
It performs high-throughput generation of siRNA duplexes with built-in thermodynamic balancing and chemical modification design to enhance potency and stability.
Integrated models score off-target risk, seed homology, and immunogenicity for every candidate, linking each design to relevant patents and scientific literature. Multi-parameter filtering and ranking then prioritize the most selective, developable siRNAs for experimental validation.
The MetaAgent achieves effectively unlimited memory by batch-processing large collections of records and synthesizing structured summaries, allowing continuous awareness of all ingested content without context-window constraints.
For example, it can extract mechanism–disease–chemical relationships from the CTD database, mine modification patterns and delivery chemistries from patent corpora, and normalize experimental results from internal screening reports into unified knowledge graphs.
This curated foundation enables downstream agents to reason across heterogeneous sources, linking literature evidence, proprietary datasets, and regulatory knowledge to support more informed new drug design decisions.
What researchers and industry experts say about KumiChem™
RNA TherapeuticsKumiChem™ offers an innovative approach to integrating AI into oligonucleotide drug discovery. Its unified platform has strong potential to accelerate siRNA and other oligonucleotide therapeutics development by streamlining molecular design, optimization, and evaluation.
From an industry R&D perspective, I see meaningful opportunities for this technology to improve research efficiency and support more informed scientific decision-making. I look forward to its continued development and real-world validation.
Nucleic Acid TherapeuticsI’m very impressed by your platform and believe it has tremendous potential. Many hospitals and researchers are looking for faster, more efficient ways to design nucleic acid therapeutics that could benefit patients.
As a researcher in the nucleic acid field in the U.S., I’m excited about your work and look forward to seeing your future progress.
PharmaceuticalDeveloping a new platform for AI-based drug discovery could revolutionize the industry and lead to faster, more effective treatments.
I'm truly impressed by your courage to tackle such a challenging subject as a startup. I can't wait to see the impact your work will have on the healthcare industry.
Life ScienceTraditional drug development is typically a laborious and costly process with unavoidable ethical concerns regarding animal experiments and human trials. Employing AI can circumvent these issues and increase the efficiency of developing more effective and affordable drugs.
It is exciting to see that DLeader is providing this kind of user-friendly AI platform that enables researchers and companies to boost biomedical research and pharmaceutical development, ultimately benefiting educational purposes and public health.
MedicineThe integration of AI into medical research and clinical practice has the potential to significantly enhance patient care by providing faster, more accurate diagnoses and personalized treatment plans. Leveraging AI can optimize the use of medical data, leading to groundbreaking advancements.
We are inspired by Dleader's dedication to bringing these innovations into the healthcare field. Looking forward to seeing how your efforts will improve public health.
Information ScienceRecent research in AI and data mining has significantly accelerated the development of technologies across various domains.
We're excited to see DLeader's commitment to innovative drug development, and we anticipate it becoming a pioneering leader in this field
MathThe premise for conducting data analysis and using its results as guidelines or bases is the recognition of its validity. Validity primarily refers to "statistical significance," with criteria rooted in probability theory's Law of Large Numbers and Central Limit Theorem.
Additionally, data science's dimensionality reduction, forecasting, and classification clustering methods may also utilize highly advanced modern mathematical tools and cutting-edge theories, which contribute to the thriving field of data science and provide a solid scientific foundation for the platform.
Tell us about your team and program. We'll set up a demo and can discuss pilots or research collaboration.